CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium - PubMed (original) (raw)
Clinical Trial
. 2005 Sep 1;104(5):1045-8.
doi: 10.1002/cncr.21265.
Affiliations
- PMID: 16007689
- DOI: 10.1002/cncr.21265
Free article
Clinical Trial
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium
Kim Margolin et al. Cancer. 2005.
Free article
Abstract
Background: CCI-779 is an analog of the immunosuppressive agent, rapamycin, that has demonstrated activity against melanoma in preclinical models and shown clinical benefit in patients with breast and renal carcinoma. CCI-779 is not immunosuppressive when administered on an intermittent schedule, and its toxicity is modest, consisting of nausea, diarrhea, hypertriglyceridemia, thrombocytopenia, asthenia, and follicular dermatitis.
Methods: The current trial was designed to detect a median time to disease progression of >18 weeks in patients with metastatic melanoma treated with a 250-mg weekly dose of CCI-779 administered intravenously after diphenhydramine premedication. Patients with measurable disease, no more than one previous chemotherapy regimen for metastatic disease, and normal organ function were eligible, and patients with central nervous system involvement, P450-inducing or P450-suppressing drugs, or hypertriglyceridemia were excluded.
Results: Thirty-three patients (21 males) were treated, 21 of whom had been treated previously with chemotherapy and/or biologic agents for advanced-stage disease. One patient had a partial response lasting 2 months. The median time to disease progression and overall survival were 10 weeks and 5 months, respectively. Toxicity was mild and predominantly mucocutaneous (stomatitis, diarrhea, and rash). Hyperlipidemia was cumulative and was managed with lipid-lowering agents.
Conclusions: CCI-779 was not sufficiently active in melanoma to warrant further testing as a single agent.
Similar articles
- A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. Amato RJ, et al. Cancer. 2009 Jun 1;115(11):2438-46. doi: 10.1002/cncr.24280. Cancer. 2009. PMID: 19306412 Clinical Trial. - A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK. Hidalgo M, et al. Clin Cancer Res. 2006 Oct 1;12(19):5755-63. doi: 10.1158/1078-0432.CCR-06-0118. Clin Cancer Res. 2006. PMID: 17020981 Clinical Trial. - Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP. Motzer RJ, et al. J Clin Oncol. 2007 Sep 1;25(25):3958-64. doi: 10.1200/JCO.2006.10.5916. J Clin Oncol. 2007. PMID: 17761980 Clinical Trial. - Phase II study of weekly Kahalalide F in patients with advanced malignant melanoma.
Martín-Algarra S, Espinosa E, Rubió J, López López JJ, Manzano JL, Carrión LA, Plazaola A, Tanovic A, Paz-Ares L. Martín-Algarra S, et al. Eur J Cancer. 2009 Mar;45(5):732-5. doi: 10.1016/j.ejca.2008.12.005. Epub 2009 Jan 29. Eur J Cancer. 2009. PMID: 19186051 Clinical Trial. - CCI-779 Wyeth.
Elit L. Elit L. Curr Opin Investig Drugs. 2002 Aug;3(8):1249-53. Curr Opin Investig Drugs. 2002. PMID: 12211424 Review.
Cited by
- Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Margolin KA, Moon J, Flaherty LE, Lao CD, Akerley WL 3rd, Othus M, Sosman JA, Kirkwood JM, Sondak VK. Margolin KA, et al. Clin Cancer Res. 2012 Feb 15;18(4):1129-37. doi: 10.1158/1078-0432.CCR-11-2488. Epub 2012 Jan 6. Clin Cancer Res. 2012. PMID: 22228638 Free PMC article. Clinical Trial. - From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past.
Shadbad MA, Hajiasgharzadeh K, Derakhshani A, Silvestris N, Baghbanzadeh A, Racanelli V, Baradaran B. Shadbad MA, et al. Front Immunol. 2021 Feb 22;12:623639. doi: 10.3389/fimmu.2021.623639. eCollection 2021. Front Immunol. 2021. PMID: 33692796 Free PMC article. Review. - Targeting the mTOR signaling network for cancer therapy.
Meric-Bernstam F, Gonzalez-Angulo AM. Meric-Bernstam F, et al. J Clin Oncol. 2009 May 1;27(13):2278-87. doi: 10.1200/JCO.2008.20.0766. Epub 2009 Mar 30. J Clin Oncol. 2009. PMID: 19332717 Free PMC article. Review. - PI3K/AKT/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitro.
Wu X, Yu J, Yan J, Dai J, Si L, Chi Z, Sheng X, Cui C, Ma M, Tang H, Xu T, Yu H, Kong Y, Guo J. Wu X, et al. Cancer Biol Ther. 2018 Jul 3;19(7):584-589. doi: 10.1080/15384047.2018.1435221. Epub 2018 Apr 30. Cancer Biol Ther. 2018. PMID: 29708815 Free PMC article. - Unraveling the Wide Spectrum of Melanoma Biomarkers.
Revythis A, Shah S, Kutka M, Moschetta M, Ozturk MA, Pappas-Gogos G, Ioannidou E, Sheriff M, Rassy E, Boussios S. Revythis A, et al. Diagnostics (Basel). 2021 Jul 26;11(8):1341. doi: 10.3390/diagnostics11081341. Diagnostics (Basel). 2021. PMID: 34441278 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical